OPK-88004

Chemical compound From Wikipedia, the free encyclopedia

OPK-88004 (formerly known as LY-2452473 or TT-701) is a non-steroidal indole derivative which acts as a selective androgen receptor modulator (SARM). It has been investigated by OPKO Health for the treatment of erectile dysfunction and symptoms associated with benign prostate hyperplasia.[1][2][3]

Legal status
Quick facts Legal status, Identifiers ...
OPK-88004
Legal status
Legal status
Identifiers
  • propan-2-yl N-[(2S)-7-cyano-4-(pyridin-2-ylmethyl)-2,3-dihydro-1H-cyclopenta[b]indol-2-yl]carbamate
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H22N4O2
Molar mass374.444 g·mol−1
3D model (JSmol)
  • CC(C)OC(=O)N[C@H]1CC2=C(C1)N(C3=C2C=C(C=C3)C#N)CC4=CC=CC=N4
  • InChI=1S/C22H22N4O2/c1-14(2)28-22(27)25-17-10-19-18-9-15(12-23)6-7-20(18)26(21(19)11-17)13-16-5-3-4-8-24-16/h3-9,14,17H,10-11,13H2,1-2H3,(H,25,27)/t17-/m0/s1
  • Key:IHIWYQYVBNODSV-KRWDZBQOSA-N
Close

Research

The compound advanced to a phase II trial in benign prostatic hyperplasia, but it was terminated due to difficulty in measuring prostate size, the trial's primary endpoint.[4]

It was also tried in a study to improve quality of life in patients with prostate cancer. Although it did not cause progression of the disease and increased lean body mass, the drug did not improve sexual function.[3]

See also

References

Related Articles

Wikiwand AI